Company Website:
http://www.wongesq.com/
NEW YORK -- (Business Wire)
The Law Offices of Vincent Wong notifies investors of an investigation
concerning whether XBiotech, Inc. (“XBiotech”) (NASDAQ:XBIT) violated
federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/XBIT-Info-Request-Form-1034.
There is no cost or obligation to you.
On April 20, 2017, XBiotech announced that the European Medicines Agency
(“EMA”) had rendered a negative trend vote after meeting with the
Company to discuss its marketing authorization application (“MAA”) for
XBiotech's candidate antibody for the treatment of colorectal cancer.
Then on May 18, 2017, XBiotech announced it had received a negative
opinion for its MAA. Then on June 9, 2017, XBiotech announced it had
discontinued a Phase 3 study for the treatment after the findings “were
not sufficient to meet efficacy or the threshold for continuation.”
To learn more about the investigation of XBiotech contact Vincent Wong,
Esq. either via email vw@wongesq.com,
by telephone at 212.425.1140, or visit http://docs.wongesq.com/XBIT-Info-Request-Form-1034.
Vincent Wong, Esq. is an experienced attorney that has represented
investors in securities litigations involving financial fraud and
violations of shareholder rights. Attorney advertising. Prior results do
not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108006127/en/
Contacts:
The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax:
866-699-3880
vw@wongesq.com
Source: The Law Offices of Vincent Wong
© 2024 Canjex Publishing Ltd. All rights reserved.